Your browser doesn't support javascript.
loading
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.
Schweitzer, Finja; Laurent, Sarah; Fink, Gereon R; Barnett, Michael H; Reddel, Stephen; Hartung, Hans-Peter; Warnke, Clemens.
Affiliation
  • Schweitzer F; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne.
  • Laurent S; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne.
  • Fink GR; Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne.
  • Barnett MH; Cognitive Neuroscience, Institute of Neuroscience and Medicine (INM-3), Research Center Jülich, Jülich, Germany.
  • Reddel S; Brain and Mind Centre.
  • Hartung HP; Neuroimmunology Clinic, Concord Hospital, University of Sydney, Sydney, NSW, Australia.
  • Warnke C; Department of Neurology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany.
Curr Opin Neurol ; 32(3): 305-312, 2019 06.
Article in En | MEDLINE | ID: mdl-30985373
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunologic Factors / Multiple Sclerosis Type of study: Etiology_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans Language: En Journal: Curr Opin Neurol Journal subject: NEUROLOGIA Year: 2019 Document type: Article Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Immunologic Factors / Multiple Sclerosis Type of study: Etiology_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans Language: En Journal: Curr Opin Neurol Journal subject: NEUROLOGIA Year: 2019 Document type: Article Country of publication: United kingdom